Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ortho-McNeil gets rights to Addex's neurology compounds

Executive Summary

Addex Pharmaceuticals SA (developing therapeutics for CNS disorders) has granted Johnson & Johnson's Ortho-McNeil Pharmaceutical division exclusive worldwide rights to its ADX2 and ADX3 series of compounds that the two will jointly discover and develop. The companies will create drug candidates, which Ortho-McNeil will market, to modulate allosterical G-protein coupled receptors to treat anxiety, depression, schizophrenia, and Alzheimer's disease.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies